Key result
High altitude is linked to a ~7-HU reduction in diabetic LAD pericoronary adipose attenuation.
Why the study?
The interpretation of coronary computed tomography angiography biomarkers under chronic high-altitude exposure in type 2 diabetes populations remains uncertain.
Does chronic high-altitude exposure and type 2 diabetes affect CCTA-derived coronary phenotypes and MACE in adults with suspected coronary artery disease?
Cohort (n=174)
No
Does chronic high-altitude exposure and type 2 diabetes affect CCTA-derived coronary phenotypes and MACE in adults with suspected coronary artery disease?
Mean Difference: -6.62 (95% CI -10.32–-2.91)
p-value: p=<0.001
Chronic high-altitude hypobaric hypoxia may be associated with a more favorable coronary imaging phenotype (lower calcification and plaque burden), while diabetes worsens these markers.
Background Coronary computed tomography angiography (CCTA) provides complementary anatomical, inflammatory, calcific, and functional biomarkers, but their interpretation under chronic high-altitude exposure remains uncertain. We characterized CCTA phenotypes according to altitude and type 2 diabetes and explored associations with major adverse cardiovascular events (MACE). Methods This retrospective matched cohort with prospective outcome ascertainment included adults undergoing clinically indicated CCTA for suspected coronary artery disease. Participants were classified by high-altitude residence (≥2,500 m for ≥5 years) or low-altitude residence (<500 m) and by diabetes status, forming four groups. Propensity score matching was performed separately within diabetes strata using age, sex, body mass index, and hypertension, yielding 174 participants in 87 matched pairs. CCTA assessment included pericoronary adipose tissue (PCAT) attenuation, plaque characteristics, coronary artery calcium (CAC), coronary stenosis, and vessel-specific CT-derived fractional flow reserve (CT-FFR). Primary models evaluated altitude, diabetes, and their interaction with adjustment for age, sex, body mass index, and hypertension. Associations with MACE were explored using univariable Cox models among participants with follow-up. Results In primary covariate-adjusted analyses, diabetes was associated with higher PCAT attenuation, CAC, total plaque volume, plaque burden, and maximum stenosis and with lower left anterior descending (LAD) CT-FFR (all q ≤ 0.018). Compared with the low-altitude Han group, the high-altitude Tibetan group had higher LAD and right coronary artery CT-FFR and lower CAC and plaque burden (all q ≤ 0.037). Among 13 interaction tests, only the altitude × diabetes interaction for LAD-PCAT remained significant after false discovery rate correction (−6.62 HU; 95% CI, −10.32 to −2.91; raw P < 0.001; q = 0.008). Among 119 participants with follow-up, 20 MACE occurred over a median of 28 months. Exploratory univariable analyses showed large but imprecise associations of diabetes and high-risk plaque with MACE, whereas altitude was not statistically associated with MACE ( P = 0.557). Conclusion Diabetes was associated with a more adverse coronary CCTA phenotype, whereas the high-altitude Tibetan group showed lower CAC and plaque burden and higher vessel-specific CT-FFR than the low-altitude Han group. The association between diabetes and LAD-PCAT attenuation differed between these groups. These findings warrant validation in larger, ethnically comparable longitudinal cohorts.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) conducted a cohort in Suspected coronary artery disease (n=174). High-altitude residence and type 2 diabetes vs. Low-altitude residence and non-diabetic controls was evaluated on Altitude by diabetes interaction for left anterior descending artery pericoronary adipose tissue (LAD-PCAT) attenuation (interaction estimate -6.62 HU, 95% CI -10.32 to -2.91, p=<0.001). Diabetes was associated with adverse coronary CCTA phenotypes, whereas high-altitude Tibetan residents had lower CAC and plaque burden, with a significant altitude by diabetes interaction for LAD-PCAT attenuation (-6.62 HU).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: